Personalis Unveils Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 15 2025
0mins
Source: Newsfilter
Stock Option Grant: Personalis, Inc. announced the grant of a non-qualified stock option to its new Senior Vice President, Chief Information Officer, allowing the purchase of 440,000 shares at an exercise price of $5.93 per share, as part of its 2020 Inducement Plan.
Inducement Plan Details: The stock option vests over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, contingent on continued service, in compliance with Nasdaq Listing Rules.
Analyst Views on PSNL
Wall Street analysts forecast PSNL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSNL is 11.17 USD with a low forecast of 10.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.320
Low
10.00
Averages
11.17
High
12.00
Current: 10.320
Low
10.00
Averages
11.17
High
12.00
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
